Can a doctor prescribe Mounjaro for weight loss in the UK?

What the official guidance says about prescribing Mounjaro for weight loss

Mounjaro's UK licence, granted by the MHRA, covers weight management alongside a reduced-calorie diet and increased physical activity. NICE's appraisal of tirzepatide (TA1026, published December 2024) recommends it on the NHS for adults with a BMI of 35 or above and at least one weight-related comorbidity. That clinical guidance is what shapes whether a GP can refer you through NHS routes.

The evidence behind the prescribing decision is substantial. The SURMOUNT-1 trial, involving 2,539 adults with obesity and no diabetes, found average body-weight reductions of around 20–21% at the highest dose over 72 weeks. A subsequent head-to-head study (SURMOUNT-5, published in the New England Journal of Medicine in 2025) showed tirzepatide produced greater average weight loss than semaglutide 2.4mg over the same timeframe. Prescribers draw on this kind of evidence when weighing up treatment options with patients.

Critically, the licence and the NICE recommendation are not the same thing. A private independent prescriber can work to the wider licensed threshold (BMI ≥30, or ≥27 with a qualifying condition), whereas NHS prescribing currently follows the stricter NICE criteria and the phased rollout schedule. Both routes require a genuine clinical assessment, the medicine does not change, but the route to it does.

What your GP can and cannot do on the NHS right now

GPs gained the ability to prescribe Mounjaro in primary care from April 2026 under the new QOF contract, but participation is optional and varies by practice and area. Even where a GP can prescribe it, the NHS criteria are tighter than the licensed threshold. The current NHS eligibility requires a BMI of 40 or above alongside four or more qualifying conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes). A second cohort (BMI 35–39.9 with four or more of those conditions) became eligible in June 2026.

So if your GP says they cannot prescribe Mounjaro for weight loss right now, that is almost certainly a reflection of where you sit in the phased rollout rather than a judgement about whether treatment would help you. It is worth understanding what your GP can offer and what the alternatives are before assuming the answer is simply no. Waiting lists through specialist services also exist for Wegovy under TA875, so NHS access is not a single straightforward channel.

NHS prescribing also requires patients to take part in wraparound lifestyle support, diet and activity programmes are part of the package, not optional extras. That structure works well for many people; others find the waiting time or the eligibility bar is the obstacle.

Private prescribing: who can do it and how the process works

Outside the NHS, any registered independent prescriber with the clinical competence to assess weight management can prescribe Mounjaro privately. That includes doctors and, since prescribing rights were extended, pharmacist independent prescribers. The key legal requirement is the same regardless of professional title: a proper clinical assessment before any prescription is issued.

At nume, every consultation is personally read by a GPhC-registered independent prescriber on the same day it is submitted. There is no algorithm making the call. Identity is verified by photo ID, weight is confirmed on a live video check, and your GP is notified in line with GPhC guidance. If treatment is clinically appropriate and your order arrives before noon on a working day, your medicine is dispatched the same day and delivered free the next working day by DPD, in plain packaging.

If you are thinking about timing (whether to start before a holiday, around a pay cycle, or at the beginning of a new week) those are practical questions worth raising at consultation stage. The clinical team can talk through what fits your schedule. For a full picture of how doctors and prescribers assess Mounjaro requests, that detail is covered separately.

What a prescriber is actually assessing, and why that protects you

A clinical assessment for Mounjaro is not a tick-box exercise. The prescriber is checking BMI against the licensed threshold, reviewing your current medicines for interactions, looking at your medical history for contraindications (a personal or family history of medullary thyroid carcinoma, for instance, or a history of pancreatitis), and considering whether any alternative would suit you better. The NHS medicines page for tirzepatide sets out the full range of conditions and medicines that require prescriber review before starting.

For women on oral contraceptives, there is a specific interaction worth knowing: tirzepatide can affect absorption of the pill during the first four weeks of treatment and for four weeks after each dose increase, so a non-oral contraceptive method should be added during those windows. That is the kind of detail a proper assessment catches. You can find guidance on Mounjaro's mechanism and clinical profile if you want a fuller picture before your consultation.

One practical note on cost: private treatment pricing varies by dose and provider, and what looks like a lower headline price often excludes the consultation, prescription fee, delivery or aftercare. If you want to understand what goes into a private Mounjaro price, the cost context page covers the market clearly. Prescription medicines are not somewhere to let price be the only guide. Once you are ready, check your eligibility with our prescribers, no referral needed.